Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 22 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

11Total
Not Applicable (2)
P 1 (2)
P 2 (6)
P 3 (1)

Trial Status

Recruiting10
Completed7
Unknown3
Enrolling By Invitation1
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (22)

Showing 20 of 20 trials
NCT07405164Phase 3RecruitingPrimary

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

NCT04924075Phase 2Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT03050268Recruiting

Familial Investigations of Childhood Cancer Predisposition

NCT04074135Phase 2Recruiting

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

NCT04458935Active Not Recruiting

Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma

NCT06573723Recruiting

Institutional Registry of Rare Diseases

NCT07327164Completed

Precision Medicine for Neurocutaneous Syndromes in Western China

NCT05737602Not ApplicableEnrolling By InvitationPrimary

Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease

NCT03108066Phase 2Completed

MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)

NCT06523582Recruiting

Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients

NCT00970970CompletedPrimary

Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease

NCT03749980RecruitingPrimary

MyVHL: Patient Natural History Study

NCT06194669Recruiting

Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule Cells

NCT05424016Not ApplicableRecruiting

Propranolol and Von Hippel-Lindau Disease

NCT05810246Phase 2UnknownPrimary

68Ga-NY104 PET/CT in Von Hippel-Lindau Disease

NCT05843305Phase 1Unknown

A Study of BPI-452080 in Subjects With Solid Tumors

NCT03979833UnknownPrimary

Drivers of Hypoxia-induced Angiogenesis in Tumor Development

NCT00062166CompletedPrimary

Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease

NCT02108002Phase 1CompletedPrimary

Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)

NCT02420067RecruitingPrimary

Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients

Scroll to load more

Research Network

Activity Timeline